Match Document Document Title
9029508 Dual variable domain immunoglobulins and uses thereof  
The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease.
9018163 Modulating PDX-1 with PCIF1, methods and uses thereof  
This invention relates to PCIFl and its use as a target for the improvement of pancreatic islet β cell mass and function in diabetes. Specifically, the invention relates to the use of compounds...
9012610 Diagnostic kit for IGFBP-4 proteolytic fragments in a patient sample  
The present invention relates to a method for diagnosing a cardiovascular or cancer disease by detecting IGFBP-4 (Insulin-like Growth Factor Binding Protein-4) fragments in a patient sample....
8999331 Immunobinders directed against sclerostin  
Proteins that bind sclerostin or sclerostin and TNF are described along with there use in composition and methods for treating, preventing, and diagnosing sclerostin related diseases and for...
9000134 Reagent and kit for early diagnosis of kidney disease  
The invention provides reagents and methods for diagnosing kidney disease in a human or animal.
8999936 Antibodies specific for soluble amyloid beta peptide protofibrils and uses thereof  
The invention relates to an isolated monoclonal antibody or antigen-binding fragment thereof that (a) binds (i) wild-type Aβ 42/40 protofibril comprising N-terminal truncated Aβ forms and (ii) Aβ...
8992925 RANKL antibody-PTH/PTHrP chimeric molecules  
Chimeric molecules comprising receptor activator of NF-κB ligand (RANKL) antibodies and parathyroid hormone/parathyroid hormone-related protein (PTH/PTHrP) peptides are described. Compositions and...
8992911 Antibodies specific for sclerostin and methods for increasing bone mineralization  
Compositions and methods relating to antibodies that specifically bind to TGF-beta binding proteins are provided. These methods and compositions relate to altering bone mineral density by...
8986952 Anti-human NGF antibody  
[Task] To provide an anti-human NGF antibody or an antigen-binding fragment thereof that is excellent in safety by reducing the risk of side effects such as effects on a fetus and thrombus...
8987420 High affinity human antibodies to human angiopoietin-2  
The present invention provides antibodies that bind to angiopoietin-2 (Ang-2) and methods of using same. According to certain embodiments of the invention, the antibodies are fully human...
8987421 Chimeric and humanized anti-histone antibodies  
The present invention concerns chimeric or humanized antibodies or antigen-binding fragments thereof that comprise specific CDR sequences, disclosed herein. Preferably, the antibodies or fragments...
8975381 Anti-VEGF antibodies  
Anti-VEGF antibodies and variants thereof, including those having high affinity for binding to VEGF, are disclosed. Also provided are methods of using phage display technology with naïve libraries...
8962257 Methods for diagnosing heart failure and other cardiac diseases  
The invention relates to methods of diagnosing the severity of heart failure or a cardiac dysfunction in a subject. The invention further relates to monitoring the severity of heart failure in a...
8940305 Formulation of human antibodies for treating TNF-α associated disorders  
A liquid aqueous pharmaceutical formulation is described which has a high protein concentration, a pH of between about 4 and about 8, and enhanced stability.
8940874 Neutralizing antibodies against GDF-8 and uses therefor  
The disclosure provides novel antibodies against growth and differentiation factor-8 (GDF-8), in particular human antibodies, and antibody fragments, including those that inhibit GDF-8 activity in...
8932591 Formulation of human antibodies for treating TNF-α associated disorders  
A liquid aqueous pharmaceutical formulation is described which has a high protein concentration, a pH of between about 4 and about 8, and enhanced stability.
8926978 Antibodies directed against nerve growth factor (NGF)  
The invention relates to an isolated immunoglobulin heavy chain polypeptide and an isolated immunoglobulin light chain polypeptide that binds to Nerve Growth Factor (NGF). The invention provides...
8916157 Formulation of human antibodies for treating TNF-α associated disorders  
A liquid aqueous pharmaceutical formulation is described which has a high protein concentration, a pH of between about 4 and about 8, and enhanced stability.
8916158 Formulation of human antibodies for treating TNF-α associated disorders  
A liquid aqueous pharmaceutical formulation is described which has a high protein concentration, a pH of between about 4 and about 8, and enhanced stability.
8911741 Formulation of human antibodies for treating TNF-alpha associated disorders  
A liquid aqueous pharmaceutical formulation is described which has a high protein concentration, a pH of between about 4 and about 8, and enhanced stability.
8907067 Nucleotide and amino acid sequences relating to respiratory diseases and obesity  
This invention relates to genes identified from human chromosome 12q23-qter, which are associated with various diseases, including asthma. The invention also relates to the nucleotide sequences of...
8900817 Progastrin and liver pathologies  
Progastrin levels are determined to diagnose one or more liver pathologies.
8883724 Active antiangiogenic therapy  
Application of oligonucleotide and polypeptide sequences of molecules of the family of the vascular permeability factor (VPF), their receptors, and co-receptors, as well as their modifications, in...
8883976 Antibodies against human tweak and uses thereof  
An antibody binding to TWEAK comprising as heavy chain variable domain a CDR3H selected from the group consisting of SEQ ID NO: 8, 16 or 24.
8871518 Monoclonal antibody for analyzing high-molecular weight adiponectin and utilization of same  
A monoclonal antibody that does not show a crossreactivity with middle-molecular weight (MMW) adiponectin and specifically reacts with high-molecular weight (HMW) adiponectin alone is disclosed....
8858941 VEGF/DLL4 binding agents and uses thereof  
The present invention relates to VEGF-binding agents, DLL4-binding agents, VEGF/DLL4 bispecific binding agents, and methods of using the agents for treating diseases such as cancer. The present...
8840886 Method of treating cancer with DLL4 antagonist and chemotherapeutic agent  
The invention provides methods for treating various types of cancer/tumor by administering the combination of Dll4 antagonists, in particular, Dll4 antibodies and fragments thereof that...
8834883 Anti-VEGF antibodies and uses thereof  
Provided are monoclonal antibodies and antigen binding fragments thereof that specifically bind vascular endothelial growth factor (VEGF). The anti-VEGF monoclonal antibodies block VEGF binding to...
8834879 Methods of treating fibroproliferative disorders of the kidney or reducing kidney fibrosis  
Materials and methods for reducing cell proliferation or extracellular matrix production in a mammal are disclosed. The methods comprise administering to a mammal a composition comprising a...
8828382 Heparin-binding epidermal growth factor-like growth factor binding proteins  
Provided herein are antigen binding proteins, e.g., human and/or monoclonal antibodies that have affinity for heparin-binding epidermal growth factor-like growth factor (HB-EGF) and neutralize the...
8828386 Method for extending pregnancy by reducing intraventricular hemorrhaging in patients exhibiting at least one symptom of preeclampsia and eclampsia  
A method lessening intraventricular hemorrhage in the fetus of a gravid human patient is provided where the patient is administered a therapeutically effective amount of digoxin antibody.
8822644 Method of treating cancer comprising a VEGF-B antagonist  
The present invention relates generally to the field of cancer therapy and prophylaxis. More particularly, the present invention provides growth factor antagonists which inhibit the growth of...
8809507 SPARC binding ScFvs  
The invention provides compositions comprising SPARC binding ScFc and its use.
8802100 Formulation of human antibodies for treating TNF-alpha associated disorders  
A liquid aqueous pharmaceutical formulation is described which has a high protein concentration, a pH of between about 4 and about 8, and enhanced stability.
8802102 Formulation of human antibodies for treating TNF-α associated disorders  
A liquid aqueous pharmaceutical formulation is described which has a high protein concentration, a pH of between about 4 and about 8, and enhanced stability.
8802101 Formulation of human antibodies for treating TNF-α associated disorders  
A liquid aqueous pharmaceutical formulation is described which has a high protein concentration, a pH of between about 4 and about 8, and enhanced stability.
8802103 Compositions and methods for diagnosing and treating cancer  
Monoclonal antibodies that specifically bind to an extracellular domain of human Jagged 1 and inhibit growth of a tumor comprising cancer stem cells are described. Also described is a method of...
8795670 Formulation of human antibodies for treating TNF-alpha associated disorders  
A liquid aqueous pharmaceutical formulation is described which has a high protein concentration, a pH of between about 4 and about 8, and enhanced stability.
8795663 Soluble endoglin and uses thereof  
The invention provides isolated soluble endoglin polypeptides, nucleic acids encoding soluble endoglin polypeptides, antibodies that specifically bind soluble endoglin polypeptides, and kits...
8778699 Detection of degradation products of canine NT-proBNP  
A method for determining the amount of NT-proBNP in blood samples from animals. The method includes detecting degradation products of NT-proBNP by various methods, including using antibodies, kits...
8759297 Genetically encoded multifunctional compositions bidirectionally transported between peripheral blood and the cns  
Provided herein are compositions for increasing transport of agents across the blood-brain barrier, in some embodiments in both directions, while allowing their activity once across the barrier to...
8742075 Monoclonal antibodies against ANGPTL3  
Monoclonal antibodies that specifically bind to ANGPTL3 are provided. Monoclonal antibodies that neutralize at least one activity of ANGPTL3 are provided. Methods of treating a disorder of lipid...
8741289 Siglec 15 antibodies in treating bone loss-related disease  
Novel antibodies and antigen binding fragments that specifically binds to Sιglec-15 are described herein. In some embodiments, the antibodies or antigen binding fragments may block the biological...
8741295 PD-1 antibodies and PD-L1 antibodies and uses thereof  
The invention relates to PD-1 antibodies and PD-L1 antibodies and uses thereof.
8735546 Dual variable domain immunoglobulins and uses thereof  
Engineered multivalent and multispecific binding proteins, methods of making, and their uses in the prevention, diagnosis, and/or treatment of disease are provided.
8734802 Methods of treating vasomotor symptoms using antibodies  
The invention features methods for preventing or treating CGRP associated disorders such as vasomotor symptoms, including headaches (e.g., migraine, cluster headache, and tension headache) and hot...
8722855 Dual variable domain immunoglobulins and uses thereof  
The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease.
8716450 Dual variable domain immunoglobulins and uses thereof  
The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease.
8715941 Antibodies to LRP6  
Anti-LRP6 antibodies and antigen-binding fragments thereof, as well as pharmaceutical compositions comprising such antibodies and antigen-binding fragments are described. These anti-LRP6...
8691585 Methods for predicting pregnancy outcome in a subject by hCG assay  
The present invention provides a method of predicting pregnancy outcome in a subject by determining the amount of an early pregnancy associated molecular isoform of hCG in a sample. The present...